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The factor VIII gene, which Is defective In hemophilia A, Is located In the last megabase of the long arm of the
X chromosome. Inversions due to intrachromosomal homologous recombination between mispaired copies of
gene A located within intron 22 of the gene and about 500 kb telomerlc to it account for nearly half of all cases
of severe hemophilia A. We hypothesized that pairing of Xq with its homolog inhibits the Inversion process, and
that, therefore, the event originates predominantly in male germ cells. In all 20 informative cases In which the
inversion originated in a maternal grandparent, DNA polymorphism analysis determined that it occurred in the
male germline. In addition, all but one of 50 mothers of sporadic cases due to an inversion were carriers. Thus,
these data support the hypothesis and Indicate that factor VIII gene inversions leading to severe hemophilia A
occur almost exclusively In male germ cells.
INTRODUCTION
Hemophilia A is a common X-linked coagulation disorder, with
an incidence of about 1 in 10,000 males before the onset of
modern medical therapy (1). The disease is due to a large variety
of mutations in the factor VIE gene, which is located in the last
megabase of Xq (2). When an effort was made to characterize
all the mutations in a series of patients with hemophilia A, an
unexpected finding was obtained. Higuchi et al. were able to
identify mutations in almost every case of mild-to-moderate
hemophilia A (3), but were unable to identify the mutation in
about half of the severely affected patients (4). Subsequently,
Naylor et al. using RT-PCR of illegitimate transcripts of the
factor Vm gene could not detect an amplification product between
exons 22 and 23 of the gene in about 40% of severely affected
patients (5). Recently Lakich et al. (6) and Naylor etal.(J) found
that these patients have an inversion involving the factor VIII
gene.
The inversion results from homologous recombination between
gene A, a small, intronless gene within intron 22 of the factor
VIQ gene, and one of two additional copies of gene A located
approximately 500 kb 5' and telomeric to the factor Vm gene
(6). Intron 22, the largest intron in the gene, contains two
transcribed sequences, gene A (8) and gene B (9). Interestingly,
gene B is transcribed in the same orientation as factor VIE and
uses exons 23 to 26 of the gene (9). In contrast, the copy of gene
A within intron 22 is transcribed in the opposite direction to factor
VQI, while the two upstream copies are thought to be transcribed
in the same direction as the factor VIII gene (6). The postulated
mechanism for the inversion involves flipping of the tip of the
X chromosome, allowing homologous pairing between one of
the telomeric copies of gene A and the copy in intron 22 (6).
A single crossing over event causes a DNA inversion of roughly
600 kb, resulting in the factor VHI gene being divided into two
parts, exons 1—22 and exons 23—26, which are widely separated
and have opposite orientations. This inversion can be detected
by Southern blot analysis (6), which allows direct detection of
the factor VIQ lesion in more than 25% of patients with
hemophilia A.
Depending upon which extragenic copy of gene A is involved
in the crossing over event, two main types of inversions are
recognized. A type 1 inversion affects the distal copy, while a
type 2 inversion affects the proximal copy (6). In addition, a rare
Southern blot pattern, type 3, is thought to result from an
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Figure 1. Southern blot demonstrating the various inversion mutation types.
Genomic DNA from control individuals (lares l and 7), carrier mothers (lanes
2 and 4), and affected individuals (lanes 3, 5 and 6) digested with Bell and
hybridized to the gene A probe. Lanes 1 and 7 show the normal fragment pattern.
Lane 2 shows a type 1 carrier, lane 3 a type 1 proband, lane 4 a type 2 carrier,
lane 5 a type 2 proband, and lane 6 a type 3 proband.
Table 1. Inversion mutations in patients with severe hemophilia A
Patients studied
Inversion present
Type 1
Type 2
Type 3
135
62 (46%)
48 (77% of inversions)
12 (19% of inversions)
2 (3% of inversions)
Parent of origin of the mutation (defined from 26 sporadic cases')
Maternal Grandfather 20
Maternal Grandmother 0
Mother 1
Estimated male:female ratio of mutations 302: lb
•Five sporadic families had a carrier maternal grandmother.
•The 95% confidence interval for this value is 22-12,115.
inversion occurring in an individual carrying more than two
extragenic copies of gene A (Figure 1).
To our knowledge, inversions of this type due to homologous
recombination have not been described previously in humans and
may be unique to the factor VIE gene region, due to the intragenic
and extragenic copies of gene A, the proximity of this region
to the telomere, and its location on the long arm of the X
chromosome. In this study, we hypothesized that the X
chromosome plays an important role in the rearrangement, i.e.,
that the inversion may occur predominantly in male meiosis when
Xq is unpaired with a homolog. In female meiosis the inversion
process would be inhibited by pairing between the two X
chromosomes. Our data now support the hypothesis and show
that this common inversion originates almost exclusively in male
germ cells. Since the mutation occurs very rarely in female germ
cells, nearly all mothers of patients with inversions are carriers
of factor Vm deficiency.
RESULTS
Frequency and type of inversion in severe hemophilia A
Southern blot analysis of genomic DNA from 135 patients known
to have severe hemophilia A revealed an inversion of the factor
Vm gene in 62, or 46%. Of these inversions, 48 (77%) were
type 1, 12 (19%) were type 2 and 2 (3%) were type 3 (Table
1). Included in the type 1 group were two females with severe
hemophilia A who were heterozygous for the normal pattern and
the type 1 inversion.
allele 1
allele 2
alleles
pedigree#
1
1-1
1,2
1-2
1,2
II-1
1,2
n-2
I
m-i
1,2
n-3
Figure 2. Pedigree, Southern blot analysis and polymorphism analysis of a family
with a type 1 inversion mutation, (a) shows the pedigree, (b) shows the Bc/1
digest hybridized to the gene A probe for all available family members. The
grandfather (1-1), grandmother (1-2), and both maternal aunts (II-l and II-3) have
a normal pattern. The mother (II-2) is a carrier of the type 1 inversion mutation,
demonstrated by the normal bands (21.5 kb, 16 kb, and 14 kb) as well as two
abnormal bands (20 kb and 17.5 kb). The affected individual (UI-1) has the type
1 inversion mutation, demonstrated by the abnormal 20 kb and 17.5 kb bands
and the normal 14 kb band (which represents the uninvolved proximal extragenic
copy of gene A), (c) shows polymorphism analysis using the (CA),, microsatellite
repeat in intron 13 of the factor VHI gene, demonstrating that the affected individual
inherited the X chromosome from his maternal grandfather.
Additional case samples were ascertained through the
presentation of an individual for carrier detection or prenatal
diagnosis because of a family history of hemophilia A. In these
cases, the severity of the proband's hemophilia A could not
always be determined. Therefore, this group was not included
in the estimation of the frequency of the inversion mutation among
patients with severe hemophilia A. An additional 33 patients with
a factor VHI gene inversion were found in this group with
undefined severity, 27 with type 1 and 6 with type 2. Thus, of
a total of 95 inversions observed, 75 (79%) were type 1, 18 (19%)
were type 2, and 2 (2%) were type 3.
Parental origin of the inversion
To test the hypothesis that the inversion is more likely to occur
during male meiosis, family studies were carried out on 35
families with potentially new inversion mutations based on the
absence of a family history of hemophilia A prior to the proband.
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The analysis included 1) Southern blot for detection of the
inversion in the patient, his mother, and his maternal
grandparents, when available, and 2) determination of haplotypes
in the factor VIII gene region in the same individuals to infer
the parental origin of the inversion (Figure 2). In five families,
both the mother and maternal grandmother were found to be
carriers of the inversion despite the negative family history. In
nine other families, the mothers were carriers, but the maternal
grandmothers were not available for study. In addition to these
35 families, the mothers of 15 individuals with the inversion
mutation were studied by Southern blot analysis, and in all cases
these mothers were found to be carriers. No other family
members were available for study in these 15 families.
In 20 informative families, the mother was found to be a carrier
while the inversion was not present in either maternal grandparent
(Table 1). In all of these 20 cases, polymorphic markers
demonstrated that the X chromosome carrying the inversion
originated in the germ cells of the unaffected maternal
grandfather. The informative markers were intragenic (CA)n
repeats and biallelic restriction fragment length polymorphisms
in 16 cases, the extragenic DXS52 polymorphisms in 2, and the
extragenic DXS15 in 2 cases. The error rate for the inference
of origin is negligible when the intragenic markers are used and
roughly 2 - 3 % for the extragenic DXS52 and DXS15.
The age of the maternal grandfathers at the birth of their carrier
daughters was available in 13 cases. The mean age was 29.9 years
(range 24 to 38 years). When each grandparental age was
compared to the distribution of male reproductive age in the
general population (10), the mean age of males at conception
of the individual with the de novo inversion was at the 54th
percentile. None of the grandparental ages were in the 90th
percentile or greater (11).
In only one family (HA26), a noncarrier mother had an affected
son with a type 1 inversion. Since this was the only case of a
maternal origin of the inversion, nonmaternity and sample mixup
was excluded by analysis of 7 microsatellite polymorphisms
(D6S292, D8S133, D21S167, D14S81, D18S59, D18S53, and
CSF1R) which showed that mother and child shared one allele
at each locus. Although a low level of germinal mosaicism in
the mother cannot be excluded, it is unlikely because she also
had 10 normal sons. Therefore, the mutation in this family
probably occurred in maternal germ cells. Interestingly, the
mother was in the 97th percentile for female reproductive age
when she conceived her affected son.
Among the 95 unrelated patients with inversions, samples from
their mothers were available in 50. Of these 50 mothers, 49 (98%)
were carriers of the inversion. The only exception was that
mentioned above.
The male:female sex ratio for the origin of the mutation was
determined by Bayesian analysis (10). Since the sex ratio is very
high for the inversion, it was helpful to include families in which
the maternal grandmother is a carrier (details of calculation
available on request). The male:female sex ratio is estimated at
302:1 and the 95% confidence interval is 22 to 12,115. The upper
bound of the 95 % confidence interval is so large because the
female in family HA26 had so many normal sons. Even if the
true sex ratio were 302:1, the mutation would originate in a
female in 85 % of families with this pedigree structure. If the
mother of family HA26 had no normal sons, the estimated sex
ratio would have been reduced to 55 and the 95% confidence
interval would be 11 to 975.
DISCUSSION
We estimate that inversions of the factor VIII gene occur much
more frequently in male germ cells (302:1). We hypothesize that
mispairing leading to inversion is inhibited by pairing of the X
chromosomes in female germ cells. The factor VEQ gene and
the gene A copies all reside at the telomere of Xq, which is
generally unpaired in males. However, a pseudoautosomal region
of Xq and Yq has recently been identified which extends
approximately 400 kb from their telomeres (12). This region is
distal to the telomeric gene A copies (13). DNA polymorphism
analysis suggested the possibility of exchange between these
segments of the X and Y chromosomes (12); however, the
biological significance of this pairing in relation to the factor V n
inversion events is unknown. Because pairing of the distal Xq
region differs in male and female meiosis, this region may be
predisposed to flipping onto itself in male meiosis, allowing
homologous recombination between copies of gene A. We
estimate the frequency of the inversion event as roughly 1 in
240,000 male meioses (10~4 disease frequency x 16.6%
frequency of sporadic disease (14) x 25 % frequency of inversions)
and 1 in 70,000,000 female meioses.
It is generally believed that all regions of the human genome
are paired in meiosis with the exception of the majority of the
sex chromosomes in male meiosis. Therefore, it is likely that
the type of inversions observed in the factor VHI gene could be
generated primarily in the unpaired regions of the long arms of
the X and Y chromosomes. The inversions affecting the factor
VHI gene are mediated by repeated sequences which are 5 —10
kb in size (6), one copy of which lies within the gene, and the
inversions result in splitting of the gene and a severe disease
phenotype. It is possible that other long repeated sequences, such
as LINE1 elements, mediate similar inversions involving other
genes at the telomeres of Xq and Yq. These inversions could
either be deleterious if one copy of the repeated sequence lies
within an intron of a gene, or could merely lead to polymorphic
rearrangement of marker order if the repeated sequence lies
outside gene sequences. Although this mechanism should be more
common on Xq and Yq, our finding the origin of the inversion
in a female meiosis suggests that inversions of a similar type could
occur at low frequency at the telomeres of autosomes.
Few mutations show a marked sex bias in their origin. To date
the most pronounced sex difference is in transitions at CpG
dinucleotides in the factor IX gene which originate 11 times more
frequently in males than in females (10). The estimated
male:female ratio of all point mutations was 3.5:1 in the factor
IX gene (10). In the fragile X syndrome, expansion of the
trinucleotide repeat in the FMR1 gene from the premutation to
the full mutation occurs exclusively when the mutation is inherited
from the female (15). However, since the full mutation is absent
from sperm of fragile X males, these expansions may be mitotic,
occurring in the somatic cells of the affected offspring (16).
Expansion of trinucleotide repeats in other disorders is also
influenced by the sex of origin. In Huntington disease, the largest
increases in size of the (CAG)n repeat occur predominantly in
male transmissions (17); while in myotonic dystrophy female
transmissions tend to result in larger expansions (18). Another
mutation with a bias in the sex of origin is the 1.5 Mb duplication
within 17pl 1.2 that causes Charcot-Marie-Tooth disease type
1 A, which was shown by Palau, ex al. to originate in male meiosis
in all 9 cases studied (19). Our data for the origin of the
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inversion mutation in the factor Vm gene indicate the highest
male:female sex ratio observed to date.
If the inversion occurred during DNA replication or mitosis,
one would expect to find advanced grandpaternal age, since the
number of cell divisions increases linearly with age after puberty.
On the other hand, if the inversion occurred during the one
meiosis that all germ cells undergo, one would expect to find
the observed absence of advanced grandpaternal age.
The carrier frequency in mothers of patients with hemophilia
A is theoretically 0.67 (20). One study of 28 isolated cases of
hemophilia A in which the factor Vin gene mutations were
identified found that 13 of the 28 mutations occurred de novo
within two generations (21). This number is similar to that
expected on a theoretical basis, 15 of 28. While the carrier
frequency of 0.67 remains valid among mothers of individuals
with mild-to-moderate hemophilia A and severe disease without
an inversion, nearly all mothers of patients with the inversion
(49 of 50) are carriers of factor Vm deficiency. Thus, the empiric
risk of a mother being a carrier given that her son has severe
hemophilia A can be calculated as 0.5 + (2/3x0.5) = 0.83
(approximately half of severe hemophilia A is caused by an
inversion and nearly all of these cases have a carrier mother (thus
0.5) and the remaining half maintain the 0.67 carrier frequency).
As a result, counselling of couples with a single child with severe
hemophilia A must emphasize that there is a greater risk that
the mother is a carrier than previously suspected. However,
carrier detection and prenatal diagnosis can be quite
straightforward using Southern blot analysis, and all mothers of
sons with isolated cases of severe hemophilia A should be offered
testing for the presence of an inversion mutation.
MATERIALS AND METHODS
Samples
Blood was collected from patients and family members after informed consent
was obtained. Samples were received from the following hemophilia clinics:
Vanderbilt University, Children's Orthopedic Hospital of Los Angeles, Mayo
Clinic, University of Mflnster, Cantonal Hospital of Geneva, and the gene
diagnostic laboratory of the Johns Hopkins Hospital. DNA was isolated by phenol-
chloroform extraction (22) and stored at -20°C prior to use.
Southern blots
Genomic DNA (5 ^g per reaction) was digested with Bell for 16 h at 50°C, the
digest was subjected to electropboresis for 24 h at 50 V on 0.7% agarose gels
and the DNA fragments were transferred to nitrocellulose membranes. The
membranes were probed with the 0.9 kb EcoRUSsA fragment from intron 22
containing gene A. The fragment was prepared from plasmid p482.6 (ATCC
catalogue no. 57203) as previously described (8). Southern Wots were prehybridized
and hybridized in QuilcHyb hybridization solution (Stratagene).
Polymorphic markers
The following polymorphic markers were used to determine the parental origin
of the factor VIH gene inversion: BcR from intron 18 (23), (CA)n microsatellite
repeat in intron 13 (24), (CA)n microsatellite repeat in intron 22 (25), Xbal
polymorphic site in intron 22 (26), Bgia site of locus DXS15 (27), and the VNTR
polymorphisms at loci DXS52 detected by Taql (28). Information concerning
the oligonucleoode primers or the hybridization probes for the detection of these
polymorphisms can be found in the Genome Data Base. Microsatellite detection
was performed as previously described (29).
Analysis of sex ratio
The ratio of mutation rates, r, for male: female was estimated by the method of
maximum likelihood. First, the probability of observing each pedigree was
calculated. The calculation of this probability allowed for four possible events
for each pedigree: 1) the mother was the source of the mutation, 2) the grandfather
was the source of the mutation, 3) the grandmother was the source of the mutation,
or 4) the grandmother was a carrier. Under each event, the probability of the
pedigree was determined using Bayesian calculations (10), and these four
probabilities sum to one. The likelihood of all 26 pedigrees was then calculated
by multiplying the probabilities of the observed events across all pedigrees. The
resulting likelihood depends only on r, allowing calculations of the maximum
likelihood estimate of r. The likelihood ratio statistic was used to test if r was
significantly different from 1, and to construct a 95% confidence interval for r.
Analysis of parental age
The age percentile for each family was determined using tables published in
Statistical Abstracts of the United States or Vital Statistics of the United States
(11). Birth rate per 1000 individuals in age groups of five years were multiplied
by the total Caucasian male or female U.S. population for that age group. Once
an exact natality number was calculated for each age group, the number was divided
in five equal percentages to estimate the total natality for each individual age.
Percentiles were calculated by adding all nativity numbers from age 15 to the
age in question and dividing by the total natality number for that year. Prior to
1937, only maternal ages are listed. Thus, the relatively constant ratio of maternal
to paternal age was utilized to estimate natality versus paternal age prior to 1937.
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